Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Hope for paralysis patients as Japan’s first stem cell clinical trial finds improved motor function

TOKYO, March 22 — A stem cell treatment helped improve the motor function of two out of four patients with a spinal cord injury in the first clinical study of its kind, Japanese scientists said.

There is currently no effective treatment for paralysis caused by serious spinal cord injuries, which affect more than 150,000 patients in Japan alone, with 5,000 new cases each year.

Researchers at Tokyo’s Keio University are conducting their study using induced pluripotent stem cells (iPS) – created by stimulating mature, already specialised, cells back into a juvenile state.

They can then be prompted to mature into different kinds of cells, with the Keio researchers using iPS-derived cells of the neural stem.

The university said on Friday that the motor function score for two patients improved after an operation to implant more than two million iPS-derived cells into a spinal cord.

No serious adverse event was observed for all four cases after a year of monitoring, the university said.

The research’s main goal was to study the safety of injecting the cells.

Public broadcaster NHK reported that one of the two was an elderly man who suffered the injury in an accident.

He is now able to stand without support and has started practising walking, NHK said.

“We were able to achieve results in the world’s first spinal cord treatment with iPS,” Hideyuki Okano, a Keio professor who heads the research, said, according to NHK.

Okano said the team hoped to move to a clinical trial that would be a step towards bringing the treatment to patients.

The university received government approval for their initial study in 2019 and they carried out the first operation in 2022.

Details of the patients remain confidential, but the team is focusing on people who were injured 14-28 days before the operation.

The number of cells implanted was determined after safety experiments in animals. — AFP